Media stories about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioverativ earned a news impact score of 0.23 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.0635983997419 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s analysis:

Bioverativ (NASDAQ:BIVV) opened at 56.69 on Tuesday. The company has a market capitalization of $6.13 billion and a P/E ratio of 13.48. The firm has a 50 day moving average of $56.33 and a 200-day moving average of $56.33. Bioverativ has a 52 week low of $41.88 and a 52 week high of $57.82.

Bioverativ (NASDAQ:BIVV) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.17. The company had revenue of $289.10 million during the quarter, compared to the consensus estimate of $269.00 million. The firm’s revenue was up 37.5% compared to the same quarter last year. During the same period last year, the company posted $0.59 EPS. On average, analysts forecast that Bioverativ will post $2.90 earnings per share for the current year.

Several equities analysts recently issued reports on BIVV shares. Jefferies Group LLC reissued a “buy” rating and set a $70.00 price target (up from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $80.00 price target on shares of Bioverativ in a report on Friday, August 4th. Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Wednesday, September 20th. Deutsche Bank AG started coverage on shares of Bioverativ in a report on Friday, June 23rd. They set a “hold” rating and a $65.00 price target for the company. Finally, Zacks Investment Research raised shares of Bioverativ from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $61.20.

COPYRIGHT VIOLATION WARNING: “Bioverativ (BIVV) Given News Sentiment Score of 0.23” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/26/bioverativ-bivv-given-news-sentiment-score-of-0-23.html.

In related news, Director Brian S. Posner bought 1,000 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was purchased at an average price of $59.19 per share, with a total value of $59,190.00. Following the completion of the acquisition, the director now owns 6,693 shares of the company’s stock, valued at $396,158.67. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Diantha Duvall sold 818 shares of the stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $60.47, for a total transaction of $49,464.46. Following the completion of the transaction, the insider now directly owns 2,128 shares of the company’s stock, valued at approximately $128,680.16. The disclosure for this sale can be found here.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Insider Buying and Selling by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.